Aceto amends credit and delays reporting
Aceto has restructured its finances following negotiations with lenders, securing a waiver for defaulting on key financial ratios for its financial fourth quarter ended 30 June 2018 and for all four quarters of its current financial year ending 30 June 2019. At the same time, the US firm has delayed filing its annual results from mid to late-September.
You may also be interested in...
Aceto has completed the divestment of its Rising Pharmaceuticals generics unit, is moving ahead with the disposal of its chemicals business and has disclosed a bonus incentive scheme for its CEO, William Kennally, aimed at securing the maximum value for its assets as part of bankruptcy proceedings.
Struggling US firm Aceto has filed Chapter 11 bankruptcy petitions at the same time as agreeing to divest its chemicals business assets for US$338 million, with plans to also offload its Rising Pharmaceuticals unit.
Haleon’s UK and Ireland general manager Bas Vorsteveld becomes PAGB president, replacing Perrigo's Neil Lister. Lister reflects on a turbulent four years chairing the UK industry association.